Actively Recruiting
Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study
Led by Hospital Israelita Albert Einstein · Updated on 2026-02-09
30
Participants Needed
1
Research Sites
7 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Introduction Obesity and type 2 diabetes mellitus constitute a global public health problem. Medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity are a modern therapeutic option for both diseases. Liraglutide, semaglutide, dulaglutide and tirzepatide are representatives of this drug class, whose mechanism of action results in delayed gastric emptying, reduced gastric motility and increased gastric volume. Tirzepatide, however, presents a dual agonist action, combining GLP-1 agonism with glucose-dependent insulinotropic polypeptide (GIP) agonism. The presence of gastric content during anaesthesia may lead to pulmonary aspiration and the development of chemical pneumonitis, a potentially devastating complication. However, when there is a risk factor for delayed gastric emptying, despite adequate fasting, the stomach may still present residual content, and bedside ultrasonography is an effective, non-invasive and rapid method to measure this content and stratify aspiration risk. Our hypothesis is that most individuals using tirzepatide present a full stomach even after fasting times recommended in the literature.
CONDITIONS
Official Title
Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older.
- Individuals currently using tirzepatide.
- Individuals fasting for at least 8 hours for solids and 2 hours for clear liquids without residue.
You will not qualify if you...
- Pregnant or postpartum individuals.
- Technical limitation for gastric ultrasound assessment.
- Presence of risk factors for gastroparesis.
- Use of prokinetic medications such as bromopride, metoclopramide or domperidone.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil, 05652900
Actively Recruiting
Research Team
G
Guilherme F Araujo, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here